Investor PresentationQ2FY2012-13 (1)

7/27/2019 Investor PresentationQ2FY2012-13 (1)

1/44

U

nichemLa

boratories

Limited

U

nichemLa

boratories

Limited

U

nichemLa

boratories

Limited

U

nichemLa

boratories

Limited

UnichemLaboratoriesLtd

Invest

orPresentati

on

October,2012

Invest

orPresentati

on

October,2012

1


2/44

SafeHa

rborStatement

SafeHa

rborStatement

Thispresentationmayincludecertainforward-lookingstatementsandinformation

thatinvolverisks,uncertainties

andassumptionsbas

edoncurrentexpecta

tions,

withinthe

meaningofapplicablelawsandregulations.Forward-lookingsta

tements

areallsta

tementsthatconcern

plans,objectives,goals,strategies,futureeventsor

performanceandunderlyingas

sumptionsandotherstatementsthatareotherthan

statementsofhistoricalfa

ct,including,butnotlimited

to,t

hosethatareide

ntifiedby

theuseofwordssuchasantic

ipates,

believes,estimates,

expects,intends,

plans,predicts,

projectsan

dsimilarexpressions.

Actualresultscould

differ


maeray

rom

oseproecen

orwaroongsa

emensan

ecompanyoes

notguara

nteerealizationofthe

sestatements.Anyfo

rwardlookingstatementor

informatio

ncontainedinthispresentationspeaksonlyasofthedateofthe

statements.T

hecompanyalso

disclaimsanyobligationtoreviseanyforwardlooking

statements.

Nopartofthispresentationmaybereproduced,quotedorcirculatedwitho

uttheprior

approvalfromUnichemLabora

toriesLimited

2


3/44

A

genda

A

genda

1.

Profile&

History

2.

Growth&Profitability

3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

3


4/44

Oneofthe

Indiasleadinginte

gratedPharmaceut

icalCompanieswitha

strongpresenceindomesticformulationsmarket

Ranked28th

intheDomesticFormulationsmarketas

perAWACSMATAug,2012

Am

ongstthetop#17companiesinrepresentative(c

overed)market

DomesticOperationscontrib

ute63%ConsolidatedR

evenues

Inte

rnationaloperationsgainingmomentum

2brandsfe

aturingamongtop

100brands(AWACS

MATAug,2

012)

Largestbrand/brandextensionsinexcessofRs150

Cr

Profile

Profile


ThirteenbrandswithRs.

10cr+Revenuesand3brandswaitingtocrossthisthreshold

SixteenbrandswithRs.

5cr

+Revenuesand8brand

swaitingtocrossthisthr

eshold

In1

9therapeuticsub-groupsUnichemsbrandisNo1brand,overallUnichem

sbrands

rankinthetop5in69therapeuticsub-groups

7%CAGR

Revenuegrowth(F

Y07-12):

DomesticformulationsgrowthdespiteimpactofDPC

O

Ampoxinpricereductiono

fover23%in2006

AdjustedforAmpoxinpricereduction,

thegrowthishigherthanCAGRof7%

Keyfocusedbrandsgrowing

at12%+

Zerodebt

companyandcash

generatingbusines

s

Marginalworkingcapitalbor

rowingsin2012

AWACS:MA

TAug,2

012

4


5/44

USFDA

re-certification

ofGoaPlant&

RohaPlant

SikkimPlant&

Baddi

Cephalosporin

plant

History

History--

KeyMilestones

KeyMilestones

(La

st10Years)

(La

st10Years)

JointVenture

Niche

Generics

Animal

Health

Division

Restructuring

ofUnisearch

andlaunchof

USFDA

certification

ofGoaPlant

Launchof

Specialties

Division

Acquisitionof

100%stake

inNiche

USFDA

certification

ofGhaziabad

Plant

EDQM

certification

ofRoha

Expansionof

Packaging

fac

ilityat

GO

APlant

Construction

of

R&D

Centreat

GO

Astarted


commissioned

Modernization

ofBetalactum

Plant-Baddi

SEZPithampur

construction

started

Reorganization

ofAcute

Business

2001-02

2003

-04

2005-06

2007-08

2009

NewR&D

Centreat

Mumbai

New

Biosciences

R&Dat

IISC,

Blore

divestment

Esta

blished

subsidiariesin

SouthAfrica

&Br

azil

Mod

ernization

ofG

haziabad

form

ulations

plan

t

CDD

ivision

NewPTDat

Goa

BaddiII

commissioned

Acquisitionof

APIplantat

Pithampur

Generics

Launchof

Unikare-

Derma

Division

Plant

GoaBiotech

facility

commissioned

Sikkim

Factory

construction

started

Establishment

ofpacking

unitatIreland

5

2010-11

2012


6/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

6


7/44

628

735

747

824

876

558

U

nichem

U

nichem

Consolidate

dFinancials

Consolidate

dFinancials

{Rs.

{Rs.Crores

Crores}}

GrowingSte

adily&FocusonProfitability

GrowingSte

adily&FocusonProfitability

Revenue

Revenue

2001-02

2001-02

2006-0

7

2006-0

7

2008-09

2008-09

3.0

+FoldIncrease

+10%CAGR

2009-10

2009-10

2010-11

2010-11

2011-12

(HY)

2011-12

(HY)


270

42

103

152

177

158

129

98

Rev

Rev

Ebitda

Ebitda

EBITDAas%o

fRevenue

EBITDAas%o

fRevenue

Rev

Rev

Rev

Rev

Rev

Rev

3.0

+Fold

Increase

+10%CAGR

Rev

Rev

15.7

%

15.7

%

17.6

%*

17.6

%*

7

Rev

Rev

Ebitda

EbitdaMarginin2011

Marginin2011--12declinedby9%over2009

12declinedby9%over2009--10duetoincreasedfieldheadcount,marketingspend,

10duetoincreasedfieldh

eadcount,marketingspend,

commissioningo

fadditionalplants,

higherR&D

expenditureanddepreciation

during2010

commissioningo

fadditionalplants,

higherR&D

expenditureanddepreciation

during2010--11&2011

11&2011--12.

12.

*Standalone19.4%

Ebitda

Ebitda

Ebitda

Ebitda

Ebitda

Ebitda

Ebitda

Ebitda

E

bitda

E

bitda


8/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

8


9/44

TheIndianPharma

Market

TheIndianPharma

Market

CurrentEstimatedSizeofIPM(M

ATAug,2

012)isRs.

64,9

49Crores

Market

GrowthMATAug1

6.8

%

4Year

CAGR14%+

Indiaranksglobally3rdbyvolume

and12thbyvalue

th


Futuregrowthprojectionsvaryfro

manoptimistic15%p

.a.

totempered12%

p.a.

CAGR

(2012-16)of14~17%

9

Source:IMSTheGlobaluseofMedicines:Outlookthrough2016,July2012;AW

ACSMATAug,2012

DomesticMa

rket~GreatOpportunity

DomesticMa

rket~GreatOpportunity


10/44

Reve

nue&Businessareasbreak

Reve

nue&Businessareasbreak--u

p

u

p

Consolidated

ConsolidatedFYFY201

1

201

1--1212

266.9

51.9

(5.9

%)

535.7

73.4

(8.4

%)

25

.0

(2.9

%)

77.9

(8.9

%)

Reven

ueBreak-upbySegment

Rs.

Crores

RevenueBreak-upbyRegion

Rs.

Crores


55

6.6

(63.6

%)

.

R

egulatedMarkets

In

diaBusiness

E

mergingMarkets

(61.2%)

20.9

(2.4

%)

142.5

(16.2%

)

Formulation-Domestic

API-Domestic

Formulation-Exports

API-Exports

In

ternationalBusiness-US/Brazil

In

ternationalBusiness-Niche

10


11/44

Reve

nue&Businessareasbreak

Reve

nue&Businessareasbreak--u

p

u

p

Consolidated

ConsolidatedHYHY201

2

201

2--1313 28.

1

5.1%

44.5

8.0%

22.2

4.0%

38.9

7.0%

Reven

ueBreak-upbySegment

Rs.

Crores

Reven

ueBreak-upbyRegion

Rs.

Crores


353.7

63.3%

176.7

31.6

%

Re

gulatedMarkets

Ind

iaBusiness

Em

ergingMarkets

341.6

61.1

%

12.1

2.2%

.

17.7

% Formulation-Domestic

API-Domestic

Formulation-Exports

API-Exports

Intern

ationalBusiness-US/Brazil

Intern

ationalBusiness-Niche

11


12/44

Therapy

MajorRevenuecontributors:

Chroniccareaccountsfor#

65%*of

DomesticFormulationReve

nues

Acuteportfolioaccountsfor

#35%*of

DomesticFormulationReve

nues

SCENE

P

ortfolio

P

ortfolio

TherapyDominance&PriceControl

TherapyDominance&PriceControl

Therapy


Portfolio

PriceContro

l

Appx

20%ofDomesticPortfolio(in

valueterms)

areunderexistingpricingpolicy.Thesituation

willchangewithproposedpricingpolicy

Metro

nidazole(API);Ampoxin(An

ti-infective)

andZatorPlus(Spirolactumwith

Torsilomide)

areunderpricecontrol

PriceCo

ntrol

*primarySalesMATSe

pt,2

012

12


13/44

Cash

Generation

Cash

Generation

PreR&

DExpenses

PreR&

DExpenses

2007-08

2008-09

2009-10

2010-11

2011-12

2012-13

{HY}

C

umulative

PositiveCashFlow

118.3

168.4

188.7

179.6

152.1

94.5

901.6

Spending:

Spending:

R&DExpenditu

re

21.6

23.5

29.7

40.5

39.7

6.8

161.8

Rs.Cr

ores


CapitalExpenditure

80.0

45.5

44.3

84.2

106.5

41.2

401.7

InvestmentinSu

bs

5.2

19.0

10.0

11.0

14.2

5.0

64.4

DividendPayments

0

21.1

33.8

42.1

29.4

27.1

153.5

IncreaseinWork

ing

Capital

8.6

42.7

19.1

54.9

(15.4

)

(7.3

)

102.6

Others(Incl

InvestmentsinMutual

Funds)

2.9

16.6

51.8

(53.1

)

(22.3

)

21.7

17.6

13


14/44

UnicheminThe

Indian

UnicheminThe

IndianPharma

PharmaMark

et

Mark

et

Indian

PharmaceuticalMarket

MAT

Au

g,

2012

%G

th

TotalS

izeoftheMarket

674

96

16.9

Uniche

mRepresented(Covered)Market

30,898

16.2

TopC

ompaniesinCoveredMark

et

1

Ranbaxy

1,8

45

7.6

2

SunPh

arma

1,7

67

26.2

Rs.

Crores


3

GSK

1,6

46

21.6

4

Mankin

d

1,5

47

20.5

5

Alkem

1,5

08

15.3

6

Cipla

1,3

81

11.9

7

ZydusCadila

1,3

15

15.3

8

Pirama

lHealthcare(Abbott)

1,1

97

13.6

9

Lupin

1,1

81

16.7

10

Macleo

ds

1,1

26

32.2

17

Uniche

m

Labs

69

0

5.1

14

Source:AWACSMATAug,2012


15/44

Unichemisrepresentedin290su

b-segments(about11

%oftotalsub-segme

nts),

Unic

hemsThe

rapyGaps

inthemarket

MAT

Aug12

ValueRs.

Crs

%o

fTotal

Value

No.ofSub-

Segments

%o

fTotal

No.of

Segments

UnichemNon-RepresentedSegments

36,5

98

54.2

%

2,2

44

88.6

%

UnichemReprese

ntedSegments

30,8

98

45.8

%

290

11.4

%

TotalMarket

67,4

96

100.0%

2,5

34

100.0

%


ucoversn

eary

ao

e

nvaueerms

However,op

portunitydoesexistformoreUnichemintro

ductionsinhighgrowth

non-represe

ntedsegments

Opportunityexistsinthefollow

ingTherapeuticSeg

ments:

Opportunityexistsinthefollow

ingTherapeuticSeg

ments:

HospitalProducts

WomenHealth

Nutritio

nal

Augme

ntingproductportfolioof

-

AcuteTherapy

Nephrology

15



16/44

C

hronicTherapy

AcuteTherapy

DomesticFormulations

SBUDivisions

Cardiovascular

Cardiovascular

Cardio

Cardio

--Diabeto

Diabeto

Integra

Integra

N

eu

N

euForeva

Foreva

UVA

UVA

Unikare

Unikare

Pharma

Pharma

Unifem

Unifem

Focusingon:

Focusingon:

Cardiologists,

Cardiologists,

Diabetologists

Diabetologists,,

CPs&GPs

CPs&GPs

forAnti

forAnti--

Focusingon:

Focusingon:

Cardiologists,

Cardiologists,

Diabetologists

Diabetologists,,

CPs&

FPs

CPs&

FPs

forAnti

forAnti--

Focusingon:

Focusingon:

Cardiologists,

Cardiologists,

Diabetologists

Diabetologists,,

Nephrologists,

Nephrologists,

&CPs

&CPs

Focusingon:

Focusingon:

Ne

urologists,

Ne

urologists,

Ps

ychiatrists,

Ps

ychiatrists,

&CPs

&CPs

for

Anti

for

Anti--

Focusingon:

Focusingon:

GPs&CPs

GPs&CPs

forAnti

forAnti--

Infective,

Infective,

GI,GI,

Focusingon:

Focusingon:

Ortho,

Ortho,

Derma

Derma

forAnti

forAnti--allergic,

allergic,

Antioxidants,

Antioxidants,

Focusingon:

Focusingon:

ENT,Chest,

ENT,Chest,

Criti

Criti--care

care

forAnti

forAnti--

Infective,

Infective,

Focusingon:

Focusingon:

Gynecfor

Hormones,

Ca+,

Contraceptives,


16

Unistar&

Unistar&Unimax

Unimax

Forleveraging

GenericPotential

Forleveraging

GenericPotential

,,

Statins

Statins,,

Anti

Anti--Angina

Angina

,,

Diabetes

Diabetes

manag

ements

manag

ements

&related

&related

diseases

diseases

--

Hypertensive,

Hypertensive,

Statins

Statins,,

inin--continence,

continence,

Diabetes

Diabetes

managements

managements

drugs,Anti

drugs,Anti--

de

pressants,

de

pressants,

Mo

oddisorders

Mo

oddisorders

&related

&related

products

products

--

&related

&related

products

products

,,

Haircare,

Haircare,

Cosmaceuticals

Cosmaceuticals

therapies

therapies

,

Infertilityetc.

CustomerCo

verage

CustomerCo

verage

Total#2

100+FieldForce(ClinicalBusinessAssociates)coversapprox

imately1,5

0,0

00Medicalprofessionals

(Cardiologists,

Diabetologists,

Neurologists,

Nephrologists,

Psychiatrists,

ConsultingPhysicians,

Orthopedics,

General

Physicians,

FamilyPhysicians,

Dermatologistsetc)

Therear

emorethan#4,5

00Stockistsc

overing#2,0

0,0

00retailoutlets


17/44


Business


Business

Leadershippositioninkey

participated

segments

Largestbrand/brandextensionsinexcess

ofRs150cr

#

4BrandsinTop300bra

nds

Ampoxin,

LosarH,

Losar,&Trika

47%

15%

13%

10%

2%

3%

4%

3%

2%1%

TherapeuticSegment

TherapeuticSegment--wisebreak

wisebreak--upup


In

19therapeuticgroupsU

nichems

brandisNo1brand

O

verallUnichemsbrands

rankinthe

to

p5in69therapeuticsub

-groups

H

ealthybalancebetweenchronic(65%)

&

acute(35%)

M

inimum

coverageunder

DPCO

CVs

AntiInfective

C

NS

GI

Nutritional

M

usculo-Skeletal

Anti-Diabetic

Respiratory

D

erma

Others

17



18/44

Brand

Building

Brand

Building

FocusBr

andPortfo

lio

FocusBr

andPortfo

lio

#Top10Brandscontributesnearly50%ofthecompanysdomestic

revenues

Ampoxin

Ampoxin,,Losar

Losar,,Losar

LosarH,

H,TrikaTrika,Unienzyme,TG

,Unienzyme,TG--Tor,

Tor,V

izy

lac

Vizy

lac,,Telsar

Telsar,,Olsar

Olsar,and

,andM

etride

M

etride


#50Brandscontributesappx

82%ofthecompanysdomesticreven

ues

#

3-R

s.

50+

crorebrands

#

2-R

s.

30~40crorebrands

#

8-R

s.

10~20crorebrands

#16-R

s.

5~10crorebrands

#23-R

s.

3~5crorebrands

18

Source:AW

ACSMATAug,2012


19/44

Top10ProductGroupsP

erformanc

e

Top10ProductGroupsP

erformanc

e

MATAug,

2012

%Growth

Apri~Aug

2012

%Market

Share*

%Growth

%

Contribution

toRevenue

TotalRevenue

690

5.1

296

1.0

7.9

100.0

LosarGroup

158

0.7

69

30.3

6.9

23.0

AmpoxinGroup

57

(4.0

)

23

30.1

3.2

8.2

Rs.

Cro

res


nenzyme

.

.

.

.

TelsarGroup

38

26.7

17

5.1

28.1

5.5

TrikaGroup

34

(4.7

)

15

21.5

(5.8

)

5.0

OlsarGroup

26

30.5

11

7.9

17.2

3.8

Vizylac

21

31.7

10

16.4

36.2

3.0

MetrideGroup

18

15.9

8

1.6

11.1

2.6

TG-TorGroup

17

(14.3)

7

1.8

(10.3)

2.5

ClodrelGroup

9

(15.8)

3

2.9

(20.9)

1.3

Source:AW

ACSMATAug,2012

*IPMsubgrouplevel

19


20/44

A

WACSData

A

WACSDataMATA

ug,2012

MATA

ug,2012

TherapyMarket

Segment

RepresentativeMarket

UnichemL

aboratories

Size(Rs.C

rs)

%Growth

Sa

les(Rs.

Crs)

%Share

%Growth

CardiacCare

4,8

06

21.1

322

6.7

5.2

Anti-Infectives

8,5

50

12.4

106

1.2

1.6

Neuro-Psychiatry

1,9

84

16.6

87

4.4

(2.9

)


,

.

.

.

Anti-Diabetic

2,0

41

26.9

24

1.2

7.7

Respiratory

1,0

94

14.2

22

2.0

8.3

Musculoskeletals

2,6

08

12.7

21

0.8

(12.7)

Nutraceuticals

3,0

58

16.1

17

0.6

3.2

Dermatologicals

1,1

65

23.5

14

1.2

(6.6

)

Haematinics

1,0

23

13.7

1

0.1

(23.9)

Others

1,0

76

13.9

4

0.2

257.6

TOTAL

30,8

98

16.2

690

2.2

5.1

20



21/44

AW

ACSData

AW

ACSData

MonthlySales&MAT

MonthlySales&MAT--Augus

t,2012

Augus

t,2012

Indicators

MarketSize

(Crs)

ValueGrowth

(%)

Unichem

(Crs)

ValueGrowth

(%)

%

Market

Share

MATAug12

67,4

96

16.9

690

5.1

1.0

%

Sept11

5,7

58

15.1

58

(1.4

)

1.0

%

Oct11

5,4

40

14.0

54

(2.3

)

1.0

%


,

.

.

.

Dec11

5,5

25

15.8

57

(0.0

)

1.0

%

Jan12

5,2

64

16.8

58

7.1

1.1

%

Feb12

5,2

07

18.5

54

4.8

1.0

%

Mar1

2

5,4

12

21.9

55

9.7

1.0

%

April12

5,7

41

18.0

58

4.9

1.0

%

May1

2

5,5

52

16.9

58

7.5

1.0

%

June12

5,6

39

170

58

10.1

1.0

%

July12

5,9

29

15.4

60

8.8

1.0

%

August12

6,3

14

13.8

63

8.1

1.0

%


21


22/44

GloballyAccreditedState

oftheartMa

nufacturingF

acilities

GloballyAccreditedState

oftheartMa

nufacturingF

acilities

APIs

Roha(Maharashtra)Multipurposeplants

Regulatoryapprovals-USFDA,

EDQM,

TGAandISO9001:200

0compliant

Pitham

pur(MP)Multipurposepla

nts

RegulatoryapprovalsUSFDA

,EUGMP

Formulations

Baddi(HP)essentiallycateringto

domesticmarket


-

,

,

Ghaziabad(UP)forcateringtore

gulatedanddevelopingregu

latedmarkets


ANVISA,

MHRA,

MCCandISO

9001&14000

Goa

forcateringbothtoregulated

anddevelopingregulatedmarkets


MHRA,

MCC,

ANVISA,

TGAan

dWHO

Sikkim

PlantProductionstartedin

Q1,

2010-11

Ireland

PackagingfacilityinBaldo

yle

SEZP

ithampurPlantisreadyan

dvalidationsareinprocessandexpectedtogoforregula

toryapprovals

during

theyear

Unichemi

sbuiltonthe

foundationofQ

uality&Reliability

Unichemi

sbuiltonthe

foundationofQ

uality&Reliability

22


23/44

DomesticMarke

t

DomesticMarke

tManagementFoc

us

ManagementFoc

us

Domestic

Market

Entryin

tounrepresented/un

coveredmarketsegm

ents

EnteredHospitalandGynecologysegmentsin2011-12

Produc

tPortfolioOptimization&FieldResourceAllocationrelatingtoCh

ronic

Therap

y

Enhancingrelationshipwithc

ustomersandFocus

onFieldProductivity


BrandbuildingthroughFocu

sedBrandapproach

MoreF

Ftodrivegrowth

Optima

luseofManufacturingAssets

Keyri

sks:

Highercompetitioninthedomesticmarket

Re

gulatoryhurdles

Highconcentrationrisk(Threeproductsgenerate~28%ofsales)

23


24/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

24


25/44

Internat

ionalBusiness

Internat

ionalBusiness

Comp

anyhasmadesign

ificantinvestments

inbuildinginfrastructure

tosup

portinternationalb

usiness

More

than#600product

registrationsacrosstheworld

UnichemLaboratoriesLtdore

an

eguaory

ngs

s,

s.e-

s,

s

etc)

#27U

SANDAsfiledsofarand#13ofwhic

halreadyapproved

Manymorefilingsinthepipeline

R&D

spendingisinexcessof5%ofsales

#225Scientists(including

#24PhDs)inR&Dactivities

25


26/44

InternationalBu

sinessFormulatio

ns

Z

one1:Eme

rgingGlobalMarkets

Z

one1:Eme

rgingGlobalMarkets

Strategicallian

cesinplacefordistribution

andmarketing

ofbrandedgenerics

InSAARC

countries,

S.E

Asia,

Baltic

Republics,

CIS,

CentralAsianRepublics,

Africaand

theMiddleeast

Representativeoffices

Africa,3

7%

CIS/Russia,

25%

MiddleEast,

2%

SouthEast,

36%

GeographicMixFY2

011-12


,

,

Kazakhstan(Almaty).LiaisonofficeinG

hana

Whollyowned

subsidiaryinSouthAfrica-

UNICHEMSA

(PTY)LTD

AugmentingPortfolioandOperations

WhereUnichemhasdirectoperationsth

rough

CountryManagersandTeamoflocalm

edical

representa

tives

26

Africa,

46%

CIS/Russia,

41%

MiddleEast,

2%

SouthEast,

11%

GeographicMixHY2012-13


27/44

EUROPE

EUROPENicheGenericsBusinessMod

el

NicheGenericsBusinessMod

el

Europeanpresen

cethrough100%subsidiary-Niche

Generics,

UK

Thesubsidiaryidentifiesproductsfordevelopm

ent,

recommendstheseproductstoUnichemfor

development.Int

helaterstagesofdevelopme

ntthe

subsidiarysellsth

eseregulatorydossiersand

supply

agreementstothirdpartycompanies

InternationalBu

sinessFormulatio

ns

Zone2:

Zone2:Europe

Europe

GeographicMixFY2011-12

Europe-27%

Niche-

39%

US/Canada-

34%


Total#33p

roducts{(Own:#26;In-Licensin

g:#7)

(Total#48

SKUs)}registrationscomplete

RepackingfacilityatIreland

Thesubsidiaryha

sdirectsalesoperationsintheU.K.and

RepublicofIrelan

d

Thesubsidiarytra

desacrossEuropeandhasrecently

extendeditsoper

ationsintoAustralia,

Canada

,and

SouthAfrica

Nichetofocuson

developingmarketsforgene

ricsand

identifyingpotentialproductsthatcandrivethe

business

ininUKandEuro

pe

Direct(Unichem)

presencethroughcontract

manufacturingan

dsupplyagreements

27

GeographicMixHY

2012-13

Europe-24%

Niche-28%

US/Canada-

48%

update


28/44

UINITEDSTATES:

UNICHEMP

HARMACEUTICALS

(USA)Inc-whollyow

nedsubsidiarytomanage

ANDAfilingsandBusinessDevelopment

BusinessmodelisbasedonleveragingUnichemstechnic

alexpertiseandproduction

capabilitywithintegratedend-to-e

ndvaluechain

InternationalBu

sinessFormulatio

ns

Zone2:

Zone2:

USAUSAandLA

TAM

andLA

TAM


TotalnumberofANDAsfiled#27

and#25indevelopmen

tpipeline

TotalANDAsapprovedsofor#13

Totalnumberofproductsla

unched#9

Unichemsin

vestmentsinR&Dis

increasingeveryyea

rtoensuremoreAND

Aand

DMFfilings

Companyss

trategyistoscale-up

operationsforsustain

edgrowthovertime

28


29/44

Interna

tionalMarket

Interna

tionalMarketManagementFocus

ManagementFocus

UnitedSta

tes

Develop

longtermrelationshipswithlocalpartners

Finalize

tie-upsforlaunchingANDAapprovedproducts

MoreAN

DAsfilingsandapprova

ls

Capitalizeend-to-endvaluechain

Forgere

lationshipwithInnovator

stobecomebuildingblocksinNCEResearch(contract

researchandsupplyofAPIs)


AlignwithexistingKeyRegionalPlayersacrossEurope

Rat

iopharm,

Actavis,

Mylan,

Sand

oz,Apotex

Identifyandsupportnewplayers

inemergingCEEMarkets,

Canada&Australia

Galex,

Belupo

Develop

andmanageowncomm

ercialcapabilityinUK,andIreland

Brazil

Addition

alproductregistrations

Japan

Fewpro

ductregistrations

EnhancerelationshipwithEISAI

forsupplyofGenerics/A

PIs

29


30/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

30


31/44

WorldclassManufacturing

Facilitiesand

WorldclassManufacturing

Facilitiesand

Infr

astructure

Infr

astructure

Roha(Maharashtra)Multipurp

oseplants

RegulatoryapprovalsUSFDA,E

DQM,

TGAandISO

9001:2000compliant

UnichemLaboratoriesLtdPith

ampur(MP)

Multipurpose

plants

RegulatoryauditsUSFDA,

EUGM

P

31


32/44

K

eyAPIs

K

eyAPIs

Sr.No

CurrentProductList

TherapeuticUses

USDMF

Canad

ian

DMF

EDMF/

ASMF

COS

Japanese

DMF

Technical

Package

1

AlfuzosinHydrochloride

Alphablocker

2

AmlodipineBesyla

te

AntiHypertensive

3

AmlodipineMaleat

e

AntiHypertensive

4

Aripiprazole

Antipsychotic

5

Bendroflumethiazide

AntiHypertensive,

Diuretic

6

BisprololHemifumarate

B-Blocker

**


8

BuprenorphineHydrochloride

PostOperativeA

nalgesic

9

ClonidineHydrochloride

AntiHypertensive

10

DonepezilHydroch

loride

CholinesteraseInhibitors,

Alzhemiersdisease

11

EprosartanMesyla

te

AntiHypertensive

12

Fenofibrate

*

*

13

Hydrochlorothiazid

e

AntiHypertensive,

Diuretic

**

14

Irbesartan

AntiHypertensive

*

*

15

Lacidipine

AntiParkinsons

**

**

**

16

Lamotrigine

AntiEpileptic

Available;Submitted;*UnderCompilation;**Proposedinthenear

future

32


33/44

K

eyAPIs

K

eyAPIs

Sr.No

CurrentProductLis

t

TherapeuticUses

USDMF

Canadian

DMF

EDMF

COS

Japanese

DMF

Technical

Package

17

LosartanPotassiu

m

AntiHypertensive

18

Meloxicam

COXIIInhibitor

*

19

MemantineHydro

chloride

NMDAReceptor

Antagonist,Alzheimers

disease

20

Metronidazone

AntiProtozoal/Anti

Amoebic

21

Neteglinide(Form

B)

Antidiabetic

22

Netegline(FormH

)

Antidiabetic

**

**


23

Phenylephrine

Hydrochloride

NasalDecongesta

nt

**

**

**

24

QuetiapineFumarate

AntiPsychotic

*

**

25

Telmisartan

AntiHypertensive

*

*

26

TizanidineHydrochloride

MuscleRelaxant

27

Valsartan

AntiHypertensive

**

**

**

28

ZolpidemTartrate

Hypnotic

29

Zolmitriptan

Anti-migrane

**

Available;Submitted;*UnderCompilation;

**Proposedinthenearfutu

re

Note:ReadyforCo

mmercializationBuspirone;Labetalol;PramipexoleDihy

drochloride;Ranolazine;Tam

sulosin

Hydrochloride;Tolterodine(AllforUSDMF,E

DMF/ASMFandTechnicalPackage

)

33


34/44

KeyAPIs(UnderDeve

lopment)

KeyAPIs(UnderDeve

lopment)

Sr.No

CurrentProduct

List

Therape

uticUses

USDMF

EDMF

TechnicalPackage

1

AtomoxetineHy

drochloride

Noradre

nalineReuptakeInhibitor

**

**

**

2

BepotastineBenzeneSulphonate

Antihistamine

**

**

**

3

Bimatoprost

Ant-Gla

ucoma

**

**

**

4

Brinzolamide

CarbonicAnhydraseInhibitors

**

**

**

5

CinacalcetHCl

Anti-parathyroid,

Ca-Binder

**

**

**

6

ColsevelamHC

l

Anticholeteremic,

Cholesterol

Lowerin

gAgent

**

**

**

7

Dabigatran

Thromb

inInhibitor

**

**

**

8

Dronedarone

Cardiac

Arrhythmias

**

**

**


9

DuloxetineHydrochloride

AntiDepressant

**

**

**

10

Eszopiclone

TreatmentofInsomnia

**

**

**

11

FrovatriptanSuccinate

Anti-mig

raine

**

**

**

12

Ivabradine

Antiang

inal

**

**

**

13

Milnacipran

Seroton

in-NorepinephrineReuptake

Inhibitors(SNRI)

**

**

**

14

Paliperidone

Schizop

hrenia

**

**

**

15

Prasugrel

Platelet

AggregationInhibitor

**

**

**

16

Rivastigmine

AcetylcholinesteraseInhibitor

**

**

**

17

RizatriptanBenzoate

Anti-mig

raine

**

**

**

18

SevelamerHCl

Ohosph

ateBindingAgent

**

**

**

19

Tadalafil

PDE5Inhibitor

**

**

**

20

Warfarine

Anticoagulant

**

**

**

34


35/44

Domestic

22%

Exports78%

Tota

lRevenue

RevenueBreak-upbySegment

F

Y2011-12

Domestic

22%

Exports78%

RevenueBreak-upbySegment

HY2012-13


USA/

Canada

1%

Europe,

67%

ROW

32%Exp

ortRevenueBreak-upby

Region

35

TotalRevenue:Rs.

96.5

Crores

USA/

Canada1%

Europe82%

ROW

17%

TotalRevenue:Rs.

56.3

Crores

ExportRevenueBreak-upby

Region


36/44

ManagementFocus

ManagementFocus

APIsforGenericMarkets

ImproveProfitabilityo

fAPIBusiness

FocusonprofitableG

enericAPIsto

Newcustomersin

existingRegulatedMarkets

PenetrateintoNew

RegulatedMarkets

Achievecostleadershiin

3~4molecules


LongtermSupplyCo

ntractswithcustomersinRegulatedMarketsfor

GenericAPIs

MarketinggloballyallAPIsprimarilydevelo

pedasain-houseso

urce

forGenericDosageF

ormforayforUS,

SouthAmericanmarkets,and

alsoforUKsubsidiaryforEurope

Tobecomemostcostefficientmanufacture

rforidentifiedAPIs

36


37/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

37


38/44

Focus

Focus

Unichemh

asatwofoldR&Dstrategy

Develop

mentofNovelDrugDeliverySystems(NDDS)

Develop

mentofpatentnon-infrin

gingprocessesforAPIs

ChemicalR&D

State-of-the-artfacilityatMumba

iofferingthemostcondu

civeenvironmentforvalu

eadded

research

Develop

ednovel&innovativeprocessesfor45newgene

rationmoleculesinvarious


ISO900

1certified&recognizedbyDepartmentofScience&Technology

Strongs

ynthesis&analyticalteamfullyequippedwithlate

stfacilities

Formulatio

nsR&D

State-of-the-artPharmaR&Dfa

cilitiestoundertakeformulationdevelopmentofTablets,

Capsule

s,

LiquidOrals,

Creams,

Ointments&Injectables

Separatefacilitiesforantibiotics

Pre-form

ulationlaboratoriestoca

rryoutdrug-exceipientc

ompatibilitystudiesandphysical

characterizationofAPIregarding

compressibilityandflow

characteristics

Formula

tionservicesoncontract

researchanddevelopme

ntprojectsforanumber

ofleading

Europea

ncompanies

38


39/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

39


40/44

M

anageme

nt&

M

anageme

nt&Governance

Governance

B

oardofDirectors

B

oardofDirectors

(Dr.PAMody;Mr.

(Dr.PAMody;Mr.Prafull

PrafullAnubhai

Anubhai;Mr.

;Mr.Ramdas

Ramdas

MGandhi;

MGandhi;

Mr.Nasser

Mr.NasserMunjee

Munjee;M

r.

;M

r.Prafull

PrafullDDSheth

Sheth;Mr.

;Mr.Ana

nd

Ana

ndMahajan

Mahajan))

AuditCom

mittee

AuditCom

mittee

Shareholders

Shareholders

Grievance

Grievance

Committee

Committee

Compensation

Compensation

Committee

Committee


InternalA

uditor

InternalA

uditor

Chairman&ManagingDire

ctor

Chairman&ManagingDire

ctor

DivisionalHeads

DivisionalHeads

StatutoryAuditors

StatutoryAuditors

Maintainshighstan

dardsofCorporateG

overnance

Maintainshighstan

dardsofCorporateG

overnance

CompanySecretary&

CompanySecretary&

ComplianceOfficer

ComplianceOfficer

CEO

CEOPharmaceuticals;SBU

Pharmaceuticals;SBUHeads

Heads--Salesand

Marketing;Manufacturing

Salesand

Marketing;Manufacturing

API;ManufacturingD

osage

API;ManufacturingD

osage--form;Research&Development;Quality

form;Research&Development;Quality

Assurance&Regulatory;MedicalAffairs;Finance

;Commercial&Logistics;

Assurance&Regulatory;MedicalAffairs;Finance

;Commercial&Logistics;

HumanResources;InformationTechnology;

HumanResources;InformationTechnology;Corp

orateAffairs

Corp

orateAffairs

40


41/44

A

genda

A

genda

1.

Profile&

History

2.


3.

BusinessOperations


omesc

peraons

Interna

tionalOperations

APIOperations

4.

Researc

h&Development

5.

Management&Governan

ce

6.

Financia

ls

41


42/44


43/44

Sta

ndaloneFinancials

Sta

ndaloneFinancials(SequentialQuarters)

(SequentialQuarters)

Forthree

monthsended

Sept30,2012

Forthree

monthsended

June30,2012

%Growth

SalesIncomefromOperations:

DomesticOperations

Formu

lations

17,210.6

9

16,848.80

2.1%

API

451.5

1

762.55

-40

.8%

InternationalO

perations

Formu

lations

5,810.6

1

6,562.00

-11

.5%

API

2,643.7

6

2,156.59

22

.6%

OtherOperatingIncome

308.1

1

156.16

97

.3%

TotalIncome

26,424.68

26,486.10

-0.2%

Expenditure:

MaterialConsumption

9,686.4

5

10,285.66

-5.8%

%SalesIncome

36.7%

38.8%

StaffC

ost

3,593.6

1

3,378.59

6.4%

Other

Expenditure

7,851.7

1

8,041.5

-2.4%

Particulars


43

EBITDA

5,292.91

4,780.27

10

.7%

%TotalIncome

20.0%

18.0%

Interest

66.3

9

85.76

-22

.6%

Depreciation

820.8

7

827.61

-0.8%

TotalExpenditure

22,019.03

22,619.20

-2.7%

%

TotalIncome

83.3%

85.4%

OperatingInco

me

4,405.65

3,866.90

13

.9%

%Tot

alIncome

16.7%

14.6%

OtherIncome

218.6

4

685.32

-68

.1%

ExceptionalItems(Gain/-Loss)

-

ProfitbeforeT

ax

4,624.29

4,552.22

1.6%

%Tot

alIncome

17.5%

17.2%

Priorperiodexpenses/(income)

-

IncomeTax

1,117.0

0

1,238.00

-9.8%

-

-

NetProfit

3,507.29

3,314.22

5.8%

%Tot

alIncome

13.3%

12.5%

EarningPerSh

are-Basic

3.8

8

3.67

EarningPerSh

are-Diluted

3.8

7

3.65

Exess/(short)

provisonfortaxofearlie

ryea


44/44

LaboratoriesLtd

44

Date post:	14-Apr-2018
Category:	Documents
Upload:	kapurrohit4891
View:	215 times
Download:	0 times

Investor PresentationQ2FY2012-13 (1)

Documents